LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Mai, ZhiYan"
  2. AU="Wen, Haibao"

Suchergebnis

Treffer 1 - 2 von insgesamt 2

Suchoptionen

  1. Artikel ; Online: Transapical transcatheter aortic-valve replacement for a patient with horizocardia aortic insufficiency.

    Song, Yanyan / Mai, ZhiYan / Zhang, YuJing / Zhao, Rong

    Asian journal of surgery

    2024  Band 47, Heft 5, Seite(n) 2361–2362

    Mesh-Begriff(e) Humans ; Aortic Valve Insufficiency/surgery ; Transcatheter Aortic Valve Replacement/methods ; Male ; Female ; Treatment Outcome ; Aortic Valve Stenosis/surgery ; Aortic Valve Stenosis/diagnostic imaging ; Aortic Valve Stenosis/complications ; Aged ; Aged, 80 and over
    Sprache Englisch
    Erscheinungsdatum 2024-01-19
    Erscheinungsland Netherlands
    Dokumenttyp Case Reports ; Letter
    ZDB-ID 1068461-x
    ISSN 0219-3108 ; 1015-9584
    ISSN (online) 0219-3108
    ISSN 1015-9584
    DOI 10.1016/j.asjsur.2024.01.070
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Imrecoxib and celecoxib affect sacroiliac joint inflammation in axSpA by regulating bone metabolism and angiogenesis.

    Guo, Yanke / Jiang, Dongbin / Mai, Zhiyan / Chen, Yufeng / Li, Ting / Gao, Guanmin

    Clinical rheumatology

    2023  Band 42, Heft 6, Seite(n) 1585–1592

    Abstract: Objective: To analyze the changes in the levels of bone metabolism markers related to sacroiliac joint (SIJ) inflammation in patients with axial spondyloarthritis (axSpA) after treatment with imrecoxib and celecoxib and evaluate their relationship with ... ...

    Abstract Objective: To analyze the changes in the levels of bone metabolism markers related to sacroiliac joint (SIJ) inflammation in patients with axial spondyloarthritis (axSpA) after treatment with imrecoxib and celecoxib and evaluate their relationship with clinical efficacy.
    Methods: A total of 120 patients with axSpA with at least 2 magnetic resonance imaging (MRI) SIJ scans during a 12-week follow-up were enrolled. The levels of bone metabolism markers, including dickkopf-1(DKK-1), sclerostin, vascular endothelial growth factor (VEGF), bone morphogenetic protein-2 (BMP-2), osteoprotegerin (OPG), noggin, β-catenin, and RUNX2, were measured twice, and their association with disease activity and the Spondyloarthritis Research Consortium of Canada (SPARCC) score for SIJ were analyzed by univariate analysis of covariance.
    Results: A total of 116 patients completed the follow-up. The levels of sclerostin, OPG, noggin, DKK-1, and RUNX2 were increased, whereas those of VEGF and β-catenin were decreased. The levels of sclerostin and OPG were negatively correlated with disease duration. The levels of VEGF and β-catenin were significantly decreased (F = 7.866, P = 0.003; F = 4.106, P = 0.047) in patients with disease remission. A decrease in ESR was significantly correlated with decreased levels of Runx2 and SPARCC scores, with the levels of sclerostin being significantly elevated in the SPARCC-reduced group. There were no statistically significant differences between the imrecoxib and celecoxib groups (P> 0.05).
    Conclusion: Imrecoxib and celecoxib affect SIJ inflammation, disease activity, and the course of disease by regulating bone metabolism and angiogenesis in axSpA. Key Points •After treatment with imrecoxib and celecoxib, the levels of sclerostin, OPG, noggin, DKK-1, and RUNX2 were increased, whereas those of VEGF and β-catenin were decreased, correlating with the course of disease, disease activity, and SIJ inflammation. • A decrease in ESR was significantly correlated with a decrease in the levels of RUNX2 and SIJ inflammation.. • The levels of sclerostin were more significantly elevated in SIJ inflammation remission group.. •Imrecoxib and celecoxib affect SIJ inflammation by regulating bone metabolism and angiogenesis in axSpA..
    Mesh-Begriff(e) Humans ; Celecoxib/therapeutic use ; Sacroiliac Joint/pathology ; Core Binding Factor Alpha 1 Subunit ; Vascular Endothelial Growth Factor A ; beta Catenin/therapeutic use ; Sacroiliitis ; Spondylarthritis/drug therapy ; Axial Spondyloarthritis ; Magnetic Resonance Imaging/methods ; Inflammation/drug therapy ; Inflammation/pathology
    Chemische Substanzen Celecoxib (JCX84Q7J1L) ; Imrecoxib ; Core Binding Factor Alpha 1 Subunit ; Vascular Endothelial Growth Factor A ; beta Catenin
    Sprache Englisch
    Erscheinungsdatum 2023-02-17
    Erscheinungsland Germany
    Dokumenttyp Journal Article
    ZDB-ID 604755-5
    ISSN 1434-9949 ; 0770-3198
    ISSN (online) 1434-9949
    ISSN 0770-3198
    DOI 10.1007/s10067-023-06541-8
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang